Antinociceptive effect of ambroxol in rats with neuropathic spinal cord injury pain

Pharmacology Biochemistry and Behavior

Volumn 97, Issue 2, 2010, Pages 249-255

  Hama, Aldric T ^a   Plum, Ann Woodhouse ^a   Sagen, Jacqueline ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Allodynia; Hyperalgesia; Local anesthetic; Mucolytic; Off label use; Voltage gated Na+ channel

Indexed keywords

AMBROXOL; SODIUM CHANNEL;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DORSAL ROOT; DRUG DOSE COMPARISON; HEAT; HYPERALGESIA; MALE; MECHANICAL STIMULATION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; ROTAROD TEST; SPINAL CORD COMPRESSION; SPINAL CORD INJURY; THORACIC SPINAL CORD;

AMBROXOL; ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; HOT TEMPERATURE; HYPERALGESIA; INJECTIONS, SPINAL; MALE; MOTOR ACTIVITY; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; PHYSICAL STIMULATION; POSTURAL BALANCE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHANNEL BLOCKERS; SPINAL CORD INJURIES;

RATTUS;

EID: 77957762375     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.08.006     Document Type: Article

References (52)

1. Attal N., Rouaud J., Brasseur L., Chauvin M., Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 2004, 62:218-225.
2. Basso D.M., Beattie M.S., Bresnahan J.C. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995, 12:1-21.
3. Carlton S.M., Du J., Tan H.Y., Nesic O., Hargett G.L., Bopp A.C., et al. Peripheral and central sensitization in remote spinal cord regions contribute to central neuropathic pain after spinal cord injury. Pain 2009, 147:265-276.
4. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Meth 1994, 53:55-63.
5. Chaplan S.R., Bach F.W., Shafer S.L., Yaksh T.L. Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. Anesthesiology 1995, 83:775-785.
6. Chong C.R., Sullivan D.J. New uses for old drugs. Nature 2007, 448:645-646.
7. Coggeshall R.E., Tate S., Carlton S.M. Differential expression of tetrodotoxin-resistant sodium channels Nav1.8 and Nav1.9 in normal and inflamed rats. Neurosci Lett 2004, 355:45-48.
8. Coward K., Plumpton C., Facer P., Birch R., Carlstedt T., Tate S., et al. Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain 2000, 85:41-50.
9. Cruz-Almeida Y., Martinez-Arizala A., Widerstrom-Noga E.G. Chronicity of pain associated with spinal cord injury: a longitudinal analysis. J Rehabil Res Dev 2005, 42:585-594.
10. Cummins T.R., Sheets P.L., Waxman S.G. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain 2007, 131:243-257.
11. de Mey C., Peil H., Kolsch S., Bubeck J., Vix J.M. Efficacy and safety of ambroxol lozenges in the treatment of acute uncomplicated sore throat. EBM-based clinical documentation. Arzneimittelforschung 2008, 58:557-568.
12. Felix E.R., Cruz-Almeida Y., Widerstrom-Noga E.G. Chronic pain after spinal cord injury: what characteristics make some pains more disturbing than others?. J Rehabil Res Dev 2007, 44:703-716.
13. Ferrante F.M., Paggioli J., Cherukuri S., Arthur G.R. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Anesth Analg 1996, 82:91-97.
14. Finnerup N.B., Biering-Sorensen F., Johannesen I.L., Terkelsen A.J., Juhl G.I., Kristensen A.D., et al. Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial. Anesthesiology 2005, 102:1023-1030.
15. Fischer J., Pschorn U., Vix J.M., Peil H., Aicher B., Muller A., et al. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo-controlled trials regarding the local anaesthetic properties. Arzneimittelforschung 2002, 52:256-263.
16. Gaida W., Klinder K., Arndt K., Weiser T. Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology 2005, 49:1220-1227.
17. Hains B.C., Everhart A.W., Fullwood S.D., Hulsebosch C.E. Changes in serotonin, serotonin transporter expression and serotonin denervation supersensitivity: involvement in chronic central pain after spinal hemisection in the rat. Exp Neurol 2002, 175:347-362.
18. Hains B.C., Klein J.P., Saab C.Y., Craner M.J., Black J.A., Waxman S.G. Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci 2003, 23:8881-8892.
19. Hama A., Sagen J. Behavioral characterization and effect of clinical drugs in a rat model of pain following spinal cord compression. Brain Res 2007, 1185:117-128.
20. Hama A., Woon Lee J., Sagen J. Differential efficacy of intrathecal NMDA receptor antagonists on inflammatory mechanical and thermal hyperalgesia in rats. Eur J Pharmacol 2003, 459:49-58.
21. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88.
22. Hoffmann H. Inhalation therapy with the new antisecretory drug ambroxol (metabolite VIII of bromhexine) in otorhinolaryngology. Arzneimittelforschung 1978, 28:931-933.
23. Hudmon A., Choi J.S., Tyrrell L., Black J.A., Rush A.M., Waxman S.G., et al. Phosphorylation of sodium channel Na(v)1.8 by p38 mitogen-activated protein kinase increases current density in dorsal root ganglion neurons. J Neurosci 2008, 28:3190-3201.
24. Hulsebosch C.E., Hains B.C., Crown E.D., Carlton S.M. Mechanisms of chronic central neuropathic pain after spinal cord injury. Brain Res Rev 2009, 60:202-213.
25. Jarvis M.F., Honore P., Shieh C.C., Chapman M., Joshi S., Zhang X.F., et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA 2007, 104:8520-8525.
26. Jensen M.P., Hoffman A.J., Cardenas D.D. Chronic pain in individuals with spinal cord injury: a survey and longitudinal study. Spinal Cord 2005, 43:704-712.
27. Krafte D.S., Bannon A.W. Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr Opin Pharmacol 2008, 8:50-56.
28. Kubo W., Miyazaki S., Dairaku M., Togashi M., Mikami R., Attwood D. Oral sustained delivery of ambroxol from in situ-gelling pectin formulations. Int J Pharm 2004, 271:233-240.
29. Leffler A., Reckzeh J., Nau C. Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol 2010, 630:19-28.
30. Lin C.S., Macefield V.G., Elam M., Wallin B.G., Engel S., Kiernan M.C. Axonal changes in spinal cord injured patients distal to the site of injury. Brain 2007, 130:985-994.
31. Malerba M., Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008, 4:1119-1129.
32. McGaraughty S., Chu K.L., Scanio M.J., Kort M.E., Faltynek C.R., Jarvis M.F. A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3, 5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. J Pharmacol Exp Ther 2008, 324:1204-1211.
33. McGowan E., Hoyt S.B., Li X., Lyons K.A., Abbadie C. A peripherally acting Na(v)1.7 sodium channel blocker reverses hyperalgesia and allodynia on rat models of inflammatory and neuropathic pain. Anesth Analg 2009, 109:951-958.
34. Millan M.J. The induction of pain: an integrative review. Prog Neurobiol 1999, 57:1-164.
35. Miyazaki S., Kubo W., Itoh K., Konno Y., Fujiwara M., Dairaku M., et al. The effect of taste masking agents on in situ gelling pectin formulations for oral sustained delivery of paracetamol and ambroxol. Int J Pharm 2005, 297:38-49.
36. Omana-Zapata I., Khabbaz M.A., Hunter J.C., Bley K.R. QX-314 inhibits ectopic nerve activity associated with neuropathic pain. Brain Res 1997, 771:228-237.
37. Püschmann S., Engelhorn R. Pharmacological study on the bromhexine metabolite ambroxol (author's transl). Arzneimittelforschung 1978, 28:889-898.
38. Siddall P.J., McClelland J.M., Rutkowski S.B., Cousins M.J. A longitudinal study of the prevalence and characteristics of pain in the first 5years following spinal cord injury. Pain 2003, 103:249-257.
39. Sotgiu M.L., Biella G. Contribution of central sensitization to the pain-related abnormal activity in neuropathic rats. Somatosens Mot Res 2000, 17:32-38.
40. Turner J.A., Cardenas D.D., Warms C.A., McClellan C.B. Chronic pain associated with spinal cord injuries: a community survey. Arch Phys Med Rehabil 2001, 82:501-509.
41. Wallace M.S., Magnuson S., Ridgeway B. Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med 2000, 25:459-467.
42. Warms C.A., Turner J.A., Marshall H.M., Cardenas D.D. Treatments for chronic pain associated with spinal cord injuries: many are tried, few are helpful. Clin J Pain 2002, 18:154-163.
43. Weiser T. Comparison of the effects of four Na+ channel analgesics on TTX-resistant Na+ currents in rat sensory neurons and recombinant Nav1.2 channels. Neurosci Lett 2006, 395:179-184.
44. Weiser T. Ambroxol: a CNS drug?. CNS Neurosci Ther 2008, 14:17-24.
45. Widerstrom-Noga E.G., Felipe-Cuervo E., Yezierski R.P. Chronic pain after spinal injury: interference with sleep and daily activities. Arch Phys Med Rehabil 2001, 82:1571-1577.
46. Wiesenfeld-Hallin Z., Lindblom U. The effect of systemic tocainide, lidocaine and bupivacaine on nociception in the rat. Pain 1985, 23:357-360.
47. Woolf C.J., Wiesenfeld-Hallin Z. The systemic administration of local anaesthetics produces a selective depression of C-afferent fibre evoked activity in the spinal cord. Pain 1985, 23:361-374.
48. Yaksh T.L., Rudy T.A. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976, 17:1031-1036.
49. Yezierski R.P. Pain following spinal cord injury: pathophysiology and central mechanisms. Progress in Brain Research 2000, 429-449. Elsevier, New York. J. Sandkühler, B. Bromm, G.F. Gebhart (Eds.).
50. Yiangou Y., Birch R., Sangameswaran L., Eglen R., Anand P. SNS/PN3 and SNS2/NaN sodium channel-like immunoreactivity in human adult and neonate injured sensory nerves. FEBS Lett 2000, 467:249-252.
51. Zhang A.L., Hao J.X., Seiger A., Xu X.J., Wiesenfeld-Hallin Z., Grant G., et al. Decreased GABA immunoreactivity in spinal cord dorsal horn neurons after transient spinal cord ischemia in the rat. Brain Res 1994, 656:187-190.
52. Zhou Y., Wang Y., Abdelhady M., Mourad M.S., Hassouna M.M. Change of vanilloid receptor 1 following neuromodulation in rats with spinal cord injury. J Surg Res 2002, 107:140-144.